- BC Partners will retain a minority stake in Synthon
- BC Partners acquired a majority stake in Synthon in 2019
- The transaction is expected to close in the second quarter of 2025
BC Partners has agreed to sell its majority stake in Synthon to Goldman Sachs Alternatives.
Synthon is an international pharmaceutical company, with a platform specialized in developing, manufacturing, and out-licensing complex generic medicines.
